AIP
TOVX icon

Ameritas Investment Partners’s Theriva Biologics TOVX Stock Holding History

Ameritas Investment Partners’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1
Closed -$4K – 3044
2017
Q1 		$4K Buy
+1
New +$6.98K ﹤0.01% 2879

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Ameritas Investment Partners's TOVX Position: Q2 2017 in Review

Ameritas Investment Partners sold out of Theriva Biologics (TOVX) in Q2 2017, closing a stake of 1 share — an estimated $4K sold.

Ameritas Investment Partners first reported a position in TOVX in Q1 2017 and held it in 1 quarter. The position peaked at $4K in Q1 2017. 53 funds tracked by Wall St. Rank hold TOVX as of Q2 2017.

  • Ameritas Investment Partners reported no remaining Theriva Biologics position as of Q2 2017 after selling out during the quarter.
  • Ameritas Investment Partners sold 1 Theriva Biologics share in Q2 2017, an estimated $4K.
  • Ameritas Investment Partners first reported a position in Theriva Biologics in Q1 2017 and held it in 1 quarter.
  • Ameritas Investment Partners's Theriva Biologics position peaked at $4K in Q1 2017.
  • 53 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2017.

Based on Ameritas Investment Partners's 13F filing for Q2 2017, filed 15 Aug 2017.